Cancer treatment and research communications最新文献

{"title":"Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study","authors":"Shunsuke Kondo ,&nbsp;Yuki Katsuya ,&nbsp;Kan Yonemori ,&nbsp;Keiko Komuro ,&nbsp;Masatoshi Sugeno ,&nbsp;Toshio Kawata ,&nbsp;Dana Ghiorghiu ,&nbsp;Didier Meulendijks ,&nbsp;Noboru Yamamoto","doi":"10.1016/j.ctarc.2024.100809","DOIUrl":"10.1016/j.ctarc.2024.100809","url":null,"abstract":"<div><h3>Introduction</h3><p>We aimed to assess the safety, pharmacokinetic profile, and antitumor activity of adavosertib monotherapy in Japanese patients with advanced solid tumors.</p></div><div><h3>Materials and methods</h3><p>This was a single-center, open-label, phase I study with two consecutive cohorts (250 mg and 200 mg cohorts). Patients received adavosertib at 250 mg or 200 mg, orally once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle.</p></div><div><h3>Results</h3><p>Dose-limiting toxicities (Grade 3 febrile neutropenia) occurred in 2/6 patients in the 250 mg cohort. None of the three patients in the 200 mg cohort developed dose-limiting toxicities. The most frequent treatment-emergent adverse event was nausea (250 mg: 83.3 %; 200 mg: 100.0 %). Median time to peak drug concentration was 4.03 and 2.08 h after the first dose and 2.82 and 1.90 h after multiple dosing in the 250 and 200 mg cohorts, respectively; respective mean terminal elimination half-lives were 7.36 and 7.30 h (first dose) and 10.55 and 8.88 h (multiple dosing). Systemic exposure increased in a slightly more than dose-proportional manner. No RECIST v1.1 response was observed. Disease control rate was 0 % and 33.3 % in the 250 and 200 mg cohorts, respectively. One patient (33.3 %) in the 200 mg cohort showed a best overall response of stable disease at ≥ 8 weeks; the rest showed progressive disease.</p></div><div><h3>Conclusions</h3><p>Adavosertib 200 mg once daily was well tolerated in this patient population and no safety concerns were raised. Exposure increased in a slightly more than dose-proportional manner and limited antitumor activity was shown.</p></div><div><h3>Trial registration</h3><p>ClinicalTrials.gov, NCT04462952</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100809"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000212/pdfft?md5=d212b63478dad881ca31adfab650dc49&pid=1-s2.0-S2468294224000212-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140399516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical margin and local recurrence of ductal carcinoma in situ","authors":"Michael Co ,&nbsp;Maggie Wai Yin Fung ,&nbsp;Ava Kwong","doi":"10.1016/j.ctarc.2024.100793","DOIUrl":"10.1016/j.ctarc.2024.100793","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aims to evaluate the association between surgical margin status and local recurrence of DCIS.</p></div><div><h3>Methods</h3><p>A retrospective analysis of a prospectively maintained 20-year DCIS database was performed. &gt;=2 mm margin was defined as clear margin. Local relapse rate between the patients with clear versus close margins were analyzed with Kaplan-Meier analyses.</p></div><div><h3>Results</h3><p>654 patients were analyzed. Median age was 46.5 (Range 18 – 80). 205 (31.3%) were high grade, 194 (29.7%) were intermediate grade, 143 (21.9%) were low grade. 112 (18.3%) were unknown. 202 (30.9%) were estrogen receptor positive, 49 (7.4%) were negative, 403 (61.6%) patients were unknown.</p><p>403 (61.6%) patients received mastectomy while 251 (38.4%) patients received BCS and radiotherapy. 549 (83.9%) patients had clear surgical margin, 50 (7.7%) patients had involved (positive) resection margin, 55 (8.4%) had close margin (&lt;2 mm margin). All patients with involved margin received re-excision of margin, while 21 patients (out of 55 who had close resection margins) received re-excision of margin. Negative surgical margins were achieved after the re-excision. 34 patients with close resection margin decided not to receive re-excision but to undergo adjuvant radiotherapy.</p><p>After median follow-up of 128 months, the 10-year ipsilateral breast tumor relapse (IBTR) was 4.5% (N = 28), Of which 27 (96.4%) patients had clear margin after the initial surgical treatment of DCIS. 1 (3.6%) patient had close surgical margin. Difference in IBTR between the two groups was not statistically significant (p = 0.692).</p></div><div><h3>Conclusion</h3><p>Close surgical margin for DCIS is not associated with increased risk of IBTR.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100793"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000054/pdfft?md5=d13f2d6c6103d37ca8183ce8e46003d2&pid=1-s2.0-S2468294224000054-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma","authors":"Georgios Lavasidis ,&nbsp;Argyrios Tzamalis ,&nbsp;Ioannis Tsinopoulos ,&nbsp;Nikolaos Ziakas","doi":"10.1016/j.ctarc.2024.100796","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100796","url":null,"abstract":"<div><p>The management of periocular basal cell carcinoma (BCC) is challenging due to its proximity to the eyeball. Vismodegib, a Hedgehog pathway inhibitor, has emerged as a therapeutic option for locally advanced and metastatic BCC. To critically appraise the relevant evidence, we conducted a systematic review of observational and experimental studies assessing the efficacy and safety of vismodegib for periocular BCC. Thirty-seven trials, including 435 patients, were eligible. No randomized trials were retrieved. Complete and overall clinical response rates were 20–88 % and 68–100 %, respectively. Disease progression was observed at a maximum rate of 14 %. Recurrence rates varied between 0 % and 31 %. The most common side effects were muscle cramps, dysgeusia, weight loss and alopecia. Treatment with vismodegib improved health-related quality of life. In conclusion, vismodegib represents an important novel treatment for advanced periocular BCC, with good response rates and acceptable tolerability profile. Nevertheless, its full potential needs clarification through randomized controlled trials.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100796"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S246829422400008X/pdfft?md5=60ee179ec70ef4cc1f810ddff97803cf&pid=1-s2.0-S246829422400008X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139744462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer","authors":"Kanako Sakaeda ,&nbsp;Koji Kurose ,&nbsp;Yuki Matsumura ,&nbsp;Satoshi Muto ,&nbsp;Minoru Fukuda ,&nbsp;Nanae Sugasaki ,&nbsp;Masaaki Fukuda ,&nbsp;Shinnosuke Takemoto ,&nbsp;Hirokazu Taniguchi ,&nbsp;Takeshi Masuda ,&nbsp;Katsuhiko Shimizu ,&nbsp;Yuki Kataoka ,&nbsp;Yasuhiro Irino ,&nbsp;Yumiko Sakai ,&nbsp;Yusuke Atarashi ,&nbsp;Masatoshi Yanagida ,&nbsp;Noboru Hattori ,&nbsp;Hiroshi Mukae ,&nbsp;Masao Nakata ,&nbsp;Eiichiro Kanda ,&nbsp;Mikio Oka","doi":"10.1016/j.ctarc.2024.100830","DOIUrl":"10.1016/j.ctarc.2024.100830","url":null,"abstract":"<div><h3>Background</h3><p>NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1 antibodies (Abs).</p></div><div><h3>Methods</h3><p>This study enrolled 99 NSCLC patients who received nivolumab after chemotherapy, including 21 patients harboring <em>EGFR, ALK</em>, or <em>KRAS</em> alterations. The cutoff value (10 units/mL) of NY-ESO-1 and XAGE1 Ab was determined based on Ab levels in non-malignant controls, and NY-ESO-1/XAGE1 Abs in NSCLC were measured before nivolumab. Differences in PFS and OS between the Ab-positive and Ab-negative groups were retrospectively analyzed using Cox regression analysis after applying inverse probability of treatment weighting (IPTW).</p></div><div><h3>Results</h3><p>NY-ESO-1/XAGE1 Abs were positive in 28 NSCLC, who responded more highly to nivolumab than the Ab-negatives (response rate 50.0% vs<em>.</em> 15.5 %, <em>p</em> &lt; 0.0007). The IPTW-adjusted positives and negatives for NY-ESO-1/XAGE1 Abs were 24.5 and 70.2, respectively. The Ab-positives showed longer IPTW-adjusted PFS (HR = 0.59, 95 % CI: 0.39–0.90, <em>p</em> = 0.014) and IPTW-adjusted OS (HR = 0.51, 95 % CI: 0.32–0.81, <em>p</em> = 0.004) than the Ab-negatives. Among NSCLC harboring driver genes, the Ab-positives (<em>n</em> = 10) showed longer PFS (HR = 0.34, 95 % CI: 0.13–0.89, <em>p</em> = 0.029) and OS (HR = 0.27, 95 % CI: 0.098–0.75, <em>p</em> = 0.012) than the Ab-negatives (<em>n</em> = 11).</p></div><div><h3>Conclusion</h3><p>Our immunoassay of NY-ESO-1/XAGE1 Abs is probably useful for predicting the clinical benefit with nivolumab in NSCLC, including those harboring driver genes. These results suggest that our immunoassay may be useful in ICI monotherapy for NSCLC.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100830"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S246829422400042X/pdfft?md5=4eb5664499651bf196437cf1781c6a6c&pid=1-s2.0-S246829422400042X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined single cell and spatial transcriptome analysis reveals hedgehog pathway-related genes as potential therapeutic targets for cervical cancer","authors":"Jing Zheng ,&nbsp;Miaomiao Dou ,&nbsp;Zhenzhen WU ,&nbsp;Chunjie Zhang ,&nbsp;Bo Yang ,&nbsp;Zhijie Liu ,&nbsp;Min Zhang ,&nbsp;Fang Wang","doi":"10.1016/j.ctarc.2024.100841","DOIUrl":"10.1016/j.ctarc.2024.100841","url":null,"abstract":"<div><p>Cervical cancer (CC) remains one of the most common and deadly malignancies among women worldwide, with exceptionally high morbidity and mortality rates. The aberrant activation of the hedgehog pathway is intimately associated with tumor development and progression. Nevertheless, the potential therapeutic targets within the hedgehog pathway in CC have yet to be clearly identified. In this study, we conducted an in-depth investigation of hedgehog pathway-related genes in CC, integrating single-cell sequencing data and spatial transcriptomics. Utilizing a comprehensive scoring algorithm, we identified that myofibroblasts within CC tissue exhibit a highly enriched hedgehog pathway. Our analysis of the myofibroblast development process revealed that MYH9 plays a crucial role. Further exploration using spatial transcriptome data allowed us to delve into the role of MYH9 in myofibroblasts. We discovered that MYH9-negative and MYH9-positive myofibroblasts display distinct profiles. Validation using extensive transcriptome data demonstrated that a high infiltration of MYH9-positive myofibroblasts is a risk factor for CC patients, significantly impacting prognosis and immunotherapeutic efficacy. Our study provides unique insights into the relationship between CC and the hedgehog pathway, offering new directions for cancer treatment strategies.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100841"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000534/pdfft?md5=5683605534cdeb8e806d0fbddc2c4085&pid=1-s2.0-S2468294224000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142242176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring sex difference in the risk factors and prognosis of inoperable lung cancer","authors":"Muhammad Rafiqul Islam ,&nbsp;Syeda Masuma Siddiqua ,&nbsp;Golam Rabbani ,&nbsp;Salman Bashar Al Ayub ,&nbsp;Rashedul Islam ,&nbsp;Beauty Saha ,&nbsp;Nazrina Khatun ,&nbsp;Mohammad Hasan Shahriar ,&nbsp;Mohammad Rocky Khan Chowdhury ,&nbsp;Sheikh M Alif ,&nbsp;Md Nazmul Karim","doi":"10.1016/j.ctarc.2024.100848","DOIUrl":"10.1016/j.ctarc.2024.100848","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer remains a leading cause of cancer-related deaths globally, with increasing incidence among females. Sex differences in lung cancer risk and outcomes are influenced by various factors, including biological characteristics. In Bangladesh, where lung cancer mortality rates are high, patients often present at advanced stages. However, real-time data on sex-specific survival outcomes for inoperable lung cancer in Bangladesh is lacking.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed patients with inoperable lung cancer at the National Institute of Cancer Research and Hospital in Dhaka, Bangladesh, from 2018 to 2019. Patient demographics and clinical parameters were assessed, with survival tracked until June 2020. Statistical analyses included descriptive statistics, Chi-square tests, <em>t</em>-tests, Kaplan-Meier curves, and multivariable Cox regression models.</div></div><div><h3>Results</h3><div>Females were diagnosed at a younger age (55.3 ± 12.7 vs 60.5 ± 10.2 years, <em>p</em> &lt; 0.001) and had higher comorbidity rates (36.2 %, <em>p</em> = 0.004). Males had higher smoking rates, while females used more smokeless tobacco. Adenocarcinoma was more prevalent in females (47.2 %) and squamous cell carcinoma in males (42.7 %). After adjusting for various factors, females showed a significant survival advantage (median 16 vs 12 months), particularly in adenocarcinoma (HR: 0.64, 95 %CI:0.46–0.90, <em>p</em> = 0.01) and squamous cell carcinoma (HR: 0.52, 95 %CI:0.32–0.85, <em>p</em> = 0.009). Females also demonstrated better survival when receiving supportive care, chemotherapy, or radiotherapy alone but not in combined therapy. Older males (&gt;70), illiterate, smokers, and those with comorbidities had a poor prognosis compared to females.</div></div><div><h3>Conclusion</h3><div>This study reveals significant sex-based differences in inoperable lung cancer patients in Bangladesh. Despite earlier diagnosis and higher comorbidities, females demonstrated better survival rates, particularly in adenocarcinoma and squamous cell carcinoma. These findings highlight the need for sex-specific approaches in lung cancer management to improve patient outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100848"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailoring treatment for locally advanced rectal cancer","authors":"Laudy Chehade,&nbsp;Kristel Dagher,&nbsp;Ali Shamseddine","doi":"10.1016/j.ctarc.2024.100847","DOIUrl":"10.1016/j.ctarc.2024.100847","url":null,"abstract":"<div><div>The management of locally advanced rectal cancer (LARC) requires personalized treatment to improve outcomes and maintain quality of life. This narrative review examines the recent developments in management, focusing on non-operative management, radiotherapy choices or omission, chemotherapy sequencing, and the role of immunotherapy and brachytherapy boost. Non-operative management can be an option for select patients, and the use of long-course chemoradiation (LCCRT) with consolidation chemotherapy or brachytherapy boost has been shown to enhance rectal preservation rates. For patients requiring surgery, the choice between LCCRT and SCRT depends on the risk of local recurrence and patient preferences. MSI-high LARC patients benefit significantly from single-agent immunotherapy, and early clinical trials show promising results for the application of immunotherapy in MSS tumors. By stratifying patients based on individual and tumor risk factors, clinicians can tailor treatment plans to improve oncologic outcomes and quality of life for patients with LARC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100847"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Providers’ knowledge about and barriers to lung cancer screening","authors":"Jeffrey J. Quezada ,&nbsp;Axs R. Avenido ,&nbsp;Stephanie Jia ,&nbsp;Arsanyous Bernaba ,&nbsp;Sabrina Nguyen ,&nbsp;Shayan S. Gharagozlou ,&nbsp;Tan Q. Nguyen ,&nbsp;Hari Keshava ,&nbsp;Gelareh Sadigh","doi":"10.1016/j.ctarc.2024.100850","DOIUrl":"10.1016/j.ctarc.2024.100850","url":null,"abstract":"<div><h3>Objective</h3><div>Low dose computed tomography (LDCT) for lung cancer screening (LCS) is underutilized despite its demonstrated mortality benefit compared to chest radiography. Our study aimed to assess knowledge about LCS and barriers to ordering LDCT from the viewpoint of primary care and pulmonology providers in academic and community settings.</div></div><div><h3>Methods</h3><div>Providers of various specialties (pulmonology, family medicine, internal medicine, geriatric medicine) who were practicing in Southern California and provided care to patients aged 50 or more were asked to complete a 10-minute survey to assess knowledge about LCS criteria, and barriers to the use of LDCT scan screening. Knowledge scores were calculated for each respondent based on their responses to 9 questions based on Centers for Medicare and Medicaid Services eligibility criteria with a total score range from 0 to 9 points.</div></div><div><h3>Results</h3><div>32 eligible providers completed the survey, of which none correctly identified all CMS eligibility criteria. Average knowledge score was 6.6 ± 1.1 and did not significantly differ based on practice setting, training level, or years of practice. Common barriers to utilization of LDCT included inaccurate smoking history in the medical record (56.2 %), failure of the medical record to notify providers of eligible patients (43.7 %), and concerns about financial cost of downstream tests after a positive scan (38.7 %).</div></div><div><h3>Conclusions</h3><div>Suboptimal provider knowledge of LDCT criteria may contribute to LCS underutilization. Improvement of educational resources for providers and augmentation of EMR smart tools to update documented smoking histories and notify providers of eligible patients may improve the rate of LCS.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100850"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The status of serum 25(OH)D levels is related to breast cancer","authors":"Mohammad Momivand ,&nbsp;Mahta Razaghi ,&nbsp;Farshid Mohammadi ,&nbsp;Edris Hoseinzadeh ,&nbsp;Roya Najafi-Vosough","doi":"10.1016/j.ctarc.2025.100870","DOIUrl":"10.1016/j.ctarc.2025.100870","url":null,"abstract":"<div><h3>Aim</h3><div>Breast cancer is the second most common cancer among women and the leading cause of cancer-related mortality in this population. Numerous factors have been identified as either risk factors or protective factors for breast cancer. However, the role of Vitamin D (Vit. D) in breast cancer remains contentious, with conflicting findings in the literature. The present study aimed to compare serum Vit. D levels between women with and without breast cancer.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 40 women diagnosed with breast cancer, referred to the Mahdia Hamadan Radiotherapy Center in 2022. These participants were matched with 40 age- and Vit. D serum level-matched women without breast cancer. Serum Vit. D levels were measured using the ELISA method. Statistical analysis was performed using SPSS version 26, with a significance threshold set at a 95% confidence level.</div></div><div><h3>Results</h3><div>The mean ± standard deviation of serum Vit. D levels in women with and without breast cancer were 31.9 ± 28.27 ng/mL and 37.98 ± 15.89 ng/mL, respectively (P = 0.024). The prevalence of Vit. D insufficiency was 50% in the breast cancer group and 27.5% in the control group, while 50% of the breast cancer group and 72.5% of the control group had sufficient Vit. D levels (P = 0.008). In women with breast cancer, lower Vit. D levels were significantly associated with lower educational (P &lt; 0.001), economic (P &lt; 0.001), and social status (P &lt; 0.001). A weak positive correlation was observed between serum Vit. D levels and patient age (r = 0.162, P = 0.152).</div></div><div><h3>Conclusion</h3><div>The significant difference in serum Vit. D levels between women with and without breast cancer suggests that Vit. D deficiency may be associated with breast cancer risk. These findings support the hypothesis that improving Vit. D status in women could potentially reduce the incidence of breast cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100870"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis","authors":"Louis-Emmanuel Chriqui ,&nbsp;Etienne Abdelnour-Berchtold ,&nbsp;Edoardo Zanfrini ,&nbsp;Severine Devesa-Perez ,&nbsp;Michel Gonzalez ,&nbsp;Thorsten Krueger ,&nbsp;Kim Ellefsen ,&nbsp;Alice Destaillats ,&nbsp;David Bonnet ,&nbsp;Martin Hübner ,&nbsp;Hasna Bouchaab ,&nbsp;Michal Bassani-Sternberg ,&nbsp;Solange Peters ,&nbsp;Sabrina Cavin ,&nbsp;Jean Y Perentes","doi":"10.1016/j.ctarc.2024.100858","DOIUrl":"10.1016/j.ctarc.2024.100858","url":null,"abstract":"<div><h3>Background</h3><div>Pleural carcinosis originates from various cancers. Its management consists in systemic therapies combined to dyspnea relief procedures. Prior studies have tested hyperthermic intrathoracic chemotherapy to treat pleural carcinosis with interesting patient survival results. However, these approaches were limited by local toxicity. Pre-clinical data have shown that hyperthermia combined to local pleural chemotherapy increased the immune response against tumors. Recently, pressurized intraperitoneal aerosol chemotherapies (PIPAC) showed improved cytostatic penetration in abdominal carcinosis with a 10-fold-lower chemotherapy dose and minimal side-effects. This approach was also tested in limited numbers of patients with pleural carcinosis but never combined with hyperthermia.</div></div><div><h3>Methods</h3><div>Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) is an open-label dose-escalation phase I trial. Patients with pleural carcinosis, eligible for the surgical management of their pleural effusion can be enrolled. Cisplatin (7.5–12–5–35–70 mg/m2) heated at 39±1 °C is delivered into the thoracic cavity before the surgical effusion management. Initially, the study consists in a dose escalation of the four different cisplatin doses. The primary endpoint is the maximal tolerated dose of cisplatin administered by PITHAC. The secondary and translational endpoints are adverse events and the immune response directed against cancer following PITHAC. There is then an expansion phase at the recommended cisplatin dose on an additional 15 patients with identical outcomes.</div></div><div><h3>Discussion</h3><div>Pressurized intrathoracic delivery of chemotherapy under hyperthermic conditions was never tested so far. We plan to determine the safety of such an approach in patients managed for pleural carcinosis. If proven safe, PITHAC could be combined with systemic immunotherapies for the management of cancer.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov Identifier: NCT06281860</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100858"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}